A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study

被引:35
|
作者
Scott, Russell [1 ]
Morgan, Jerry [2 ]
Zimmer, Zachary [2 ]
Lam, Raymond L. H. [2 ]
O'Neill, Edward A. [2 ]
Kaufman, Keith D. [2 ]
Engel, Samuel S. [2 ]
Raji, Annaswamy [2 ]
机构
[1] Christchurch Sch Med, Lipid & Diabet Res Grp, Christchurch, New Zealand
[2] Merck & Co Inc, Kenilworth, NJ USA
关键词
clinical trial; dapagliflozin; sitagliptin; type; 2; diabetes; POOLED ANALYSIS; KIDNEY-DISEASE; INHIBITORS; EQUATION;
D O I
10.1111/dom.13473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim Materials and Methods To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Patients with HbA1c >= 7.0 to <= 9.5% (>= 53 to <= 80 mmol/mol) and estimated glomerular filtration rate >= 60 to <90 mL/min/1.73m(2) on metformin (>= 1500 mg/d) +/- sulfonylurea were randomized to sitagliptin 100 mg (n = 307) or dapagliflozin 5 mg titrated to 10 mg (n = 306) once daily for 24 weeks. A longitudinal data analysis model was used to test the primary hypothesis that sitagliptin is non-inferior to dapagliflozin in reducing HbA1c at Week 24, with superiority to be tested if non-inferiority is met. NCT02532855. Results Conclusions Baseline mean HbA1c (% [mmol/mol]) was 7.7 (60.9) and 7.8 (61.2), and mean eGFR (mL/min/1.73m(2)) was 79.4 and 76.9 for the sitagliptin and dapagliflozin groups, respectively. After 24 weeks, the between-group difference in least squares mean (95% CI) changes from baseline in HbA1c was -0.15% (-0.26, -0.04) (-1.67 mmol/mol [-2.86, -0.48]), P = 0.006, meeting the prespecified criteria for declaring both non-inferiority and superiority of sitagliptin versus dapagliflozin. The HbA1c goal of <7% (<53 mmol/mol) was met by 43% (sitagliptin) and 27% (dapagliflozin) of patients. No meaningful between-group difference was observed in a pre-specified analysis of 2-hour incremental postprandial glucose excursion. A review of adverse events (AEs) was notable for a lower incidence of drug-related AEs with sitagliptin compared with dapagliflozin. In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin +/- sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
引用
收藏
页码:2876 / 2884
页数:9
相关论文
共 50 条
  • [1] Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
    Raji, Annaswamy
    Xu, Zhi Jin
    Lam, Raymond L. H.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Engel, Samuel S.
    DIABETES THERAPY, 2020, 11 (10) : 2419 - 2428
  • [2] Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
    Chan, J. C. N.
    Scott, R.
    Ferreira, J. C. Arjona
    Sheng, D.
    Gonzalez, E.
    Davies, M. J.
    Stein, P. P.
    Kaufman, K. D.
    Amatruda, J. M.
    Williams-Herman, D.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07) : 545 - 555
  • [3] Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: Third agent study
    Hong, Jun Hwa
    Moon, Jun Sung
    Seong, Kayeon
    Lim, Soo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 203
  • [4] Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
    Dagogo-Jack, Samuel
    Liu, Jie
    Eldor, Roy
    Amorin, Guillermo
    Johnson, Jeremy
    Hille, Darcy
    Liao, Yuqin
    Huyck, Susan
    Golm, Gregory
    Terra, Steven G.
    Mancuso, James P.
    Engel, Samuel S.
    Lauring, Brett
    DIABETES OBESITY & METABOLISM, 2018, 20 (03) : 530 - 540
  • [5] Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study
    Frias, Juan P.
    Zimmer, Zachary
    Lam, Raymond L. H.
    Amorin, Guillermo
    Ntabadde, Catherine
    Iredale, Carol
    O'Neill, Edward A.
    Engel, Samuel S.
    Kaufman, Keith D.
    Makimura, Hideo
    Crutchlow, Michael F.
    DIABETES OBESITY & METABOLISM, 2019, 21 (05) : 1128 - 1135
  • [6] A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone
    Wang, Weiqing
    Ning, Guang
    Ma, Jianhua
    Liu, Xiaomin
    Zheng, Shaoxiong
    Wu, Fan
    Xu, Lei
    O'Neill, Edward A.
    Fujita, Kenji P.
    Engel, Samuel S.
    Kaufman, Keith D.
    Shankar, R. Ravi
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) : 693 - 699
  • [7] Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study
    Roussel, Ronan
    Duran-Garcia, Santiago
    Zhang, Yilong
    Shah, Suneri
    Darmiento, Carolyn
    Shankar, R. Ravi
    Golm, Gregory T.
    Lam, Raymond L. H.
    O'Neill, Edward A.
    Gantz, Ira
    Kaufman, Keith D.
    Engel, Samuel S.
    DIABETES OBESITY & METABOLISM, 2019, 21 (04) : 781 - 790
  • [8] Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus A meta-analysis of randomized controlled trials
    Feng, Miao
    Lv, Haihong
    Xu, Xia
    Wang, Jue
    Lyu, Wenyi
    Fu, Songbo
    MEDICINE, 2019, 98 (30)
  • [9] Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
    Fuchigami, Ayako
    Shigiyama, Fumika
    Kitazawa, Toru
    Okada, Yosuke
    Ichijo, Takamasa
    Higa, Mariko
    Hiyoshi, Toru
    Inoue, Ikuo
    Iso, Kaoru
    Yoshii, Hidenori
    Hirose, Takahisa
    Kumashiro, Naoki
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [10] Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial)
    Terauchi, Yasuo
    Yamada, Yuichiro
    Ishida, Hitoshi
    Ohsugi, Mitsuru
    Kitaoka, Masafumi
    Satoh, Jo
    Yabe, Daisuke
    Shihara, Nobuyuki
    Seino, Yutaka
    DIABETES OBESITY & METABOLISM, 2017, 19 (08) : 1188 - 1192